ALDEA Pharmaceuticals

ALDEA Pharmaceuticals is developing small molecule modulators of the aldehyde dehydrogenase (ALDH) family to treat toxic aldehyde-related diseases. This proprietary technology represents an opportunity for new products that can address novel targets across multiple therapeutic areas. For instance, ALDH activator compounds enhance the detoxification of ethanol in the alcohol metabolism pathway, treating acute symptoms and reducing long-term tissue damage and cancer risk.